News | Heart Failure | March 01, 2022

Earlier Surgical Intervention Could Stave Off Fibrosis in People with Mitral Valve Prolapse

Researchers suggest looking for advanced fibrosis in MVP patients in addition to traditional markers when deciding it’s time for surgical intervention, according to new study from the Medical University of South Carolina.

The same thing can be said for a heart with mitral valve prolapse (MVP) — as the diseased valve enlarges, the cords connected to the heart tissue feel stress and respond accordingly with stiffness and scarring, according to a recent paper in the Journal of the American Heart Association. 

Dr. Chip Norris and medical student Jordan Morningstar in the lab studying mitral valve prolapse. Photo credit: Brennan Wesley


March 1, 2022 – The larger the sail, the more wind it catches. But as that size increases, so does the stress experienced by each sheet and line connected to the canvas.

The same thing can be said for a heart with mitral valve prolapse (MVP) — as the diseased valve enlarges, the cords connected to the heart tissue feel stress and respond accordingly with stiffness and scarring, according to a recent paper in the Journal of the American Heart Association

As a common degenerative heart disease, MVP affects 2-3% of the U.S. population, or 1 in 40 people. It’s characterized by enlarged heart tissue and billowing of the mitral valve into the left atrium, according to the AHA. While it is often considered benign, physicians are careful to watch for mitral regurgitation, which is when the mitral valve doesn’t close properly and allows blood to leak backwards through it. Once MVP progresses to that stage, surgery is often required. If left untreated, it can result in a heart attack, stroke or sudden cardiac death. 

While only a tenth of patients with MVP are likely to need surgery, waiting until regurgitation symptoms occur might result in too much irreversible scarring, or fibrosis, in the heart, according to Chip Norris, Ph.D., principal investigator for the study and a professor in the regenerative medicine and cell biology department at MUSC. Too much fibrosis can result in stiff tissue and a heart that struggles to pump despite surgical intervention. 

After examining tissue biopsies from both human and mouse MVP patients as well as applicable genetic data, Norris and his research team have now shown a relationship between regionalized fibrosis in the left ventricle and the disease. This relationship points to a potential need for guideline updates, according to Jordan Morningstar, a medical student at MUSC who was involved in Norris’ study alongside fellow MUSC student Cortney Gensemer. 

“It appears the fibrosis occurring in the myocardium is already established at the time of surgery,” Morningstar said. “And it brings into question whether we need to be performing earlier surgical intervention in these patients in order to prevent the scarring from happening.”

Norris suggests not only looking for mitral regurgitation in patients but also monitoring disease progression with imaging to track the amount of fibrosis in the heart over time. Advanced fibrosis could be added to the list of traditional markers for mitral valve repair, which include shortness of breath, mitral regurgitation and left ventricular dilation. 

Norris says that this is the first study to provide direct evidence that MVP causes regionalized left ventricular fibrosis, which makes it impactful. “Understanding that the defective valve causes these changes in the left ventricle is significant,” he said. “We need to start having better ways of imaging these patients and following them more closely.” 

He also suggests surgeons performing any kind of valve procedures should look for scarring in both the wall of the left ventricle. “These findings show us that mitral valve prolapse is a disease of both the valve as well as the ventricle,” Norris said.

More research is needed to determine at what earlier point surgery would be most helpful and if it would indeed stop progressive fibrosis in that part of the heart. 

Morningstar compares myocardial fibrosis to a cut in the skin. “When you injure yourself, you have a group of cells called fibroblasts which can proliferate into the cut and lay down the proteins that help resolve the wound,” he said. “That wound gets smaller over time, but it eventually goes away, and a scar is left behind.”

The same is true for left ventricular fibrosis — that scar persists and can grow. 

Through the study, Norris, Morningstar and Gensemer showed that mechanical stretching kicks off the fibrotic pathways in the heart. As the mitral valve gets bigger, it pulls — or yanks, as Morningstar puts it — on the tissues and cords connected to the heart. These cells respond with fibrosis and stiffening to lessen the stretching that occurs. But that stiffening only makes it harder to pump blood effectively throughout the body. 

Norris plans to continue this line of research to determine if suggested changes to the surgical guidelines for MVP are needed, and he hopes these changes will provide fairer winds and easier blood circulation to patients with this degenerative heart disease.

For more information: https://web.musc.edu/

Related Content

News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
News | Cardiovascular Clinical Studies

June 1, 2022 — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced that its ...

Home June 01, 2022
Home
News | Cardiovascular Clinical Studies

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

Home May 31, 2022
Home
News | Cardiovascular Clinical Studies

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
Subscribe Now